Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2011-10-14

Clinical Trial Update: Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating high-dose Symlin (pramlintide) for Type 2 Diabetes Mellitus; the current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Symlin (pramlintide)

Snippet

Sponsor: Cheryl Rosenfeld, DO | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: UNKNOWN